Thermo Fisher Scientific Appoints Marc N. Casper President and Chief Executive Officer

WALTHAM, Mass.--(Business Wire)--
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science,
today announced that its board of directors has appointed Marc N. Casper
president, chief executive officer and a director of the company, effective
October 15, 2009. Casper currently serves as executive vice president and chief
operating officer. This announcement follows the decision of Marijn E. Dekkers
to resign as president, chief executive officer and a member of the board, in
order to become chief executive officer of Bayer AG, a global leader in
healthcare, nutrition and high-tech materials based in Germany.

Jim Manzi, chairman of the board, said, "Marc`s strong leadership at Thermo
Fisher over the past eight years and his achievements both here and in other
companies make him the natural choice to lead the company going forward. We are
delighted that he will take on this new role. With our industry-leading
position, commitment to world-class innovation and the most talented employees
in the industry, we believe that the company is well-prepared for this
transition and well-positioned to capitalize on new opportunities for growth. On
behalf of the entire board of directors, we thank Marijn for his dedication to
Thermo Fisher over the last nine years. Marijn has led the company through a
period of exciting growth and has built a strong foundation for future success."

"My years at Thermo Fisher have been some of the best in my career, and I thank
our employees, the leadership team and the board for working with me so
diligently to achieve our mutual goals for the company," said Mr. Dekkers.
"Having accomplished so much together, it`s now time for me to move on to a new
role, and I`m looking forward to the challenges of the next phase of my career.
I feel good about my move at this time because the company is very strong
financially and, in Marc`s capable hands and with the continued support of our
employees, has more growth prospects than ever."

Casper said, "I have developed great respect for the knowledge and focus of our
employees during my time at Thermo Fisher, and look forward to working with the
leadership team and the board in my new role. Thanks to the successful execution
of our strategy, demonstrated by our excellent financial track record, we have
been able to deliver solid operating performance despite challenging economic
conditions. We will work to continue to execute on our strategy for growth and
success."

Outlook Affirmed

The company today reaffirmed its full year 2009 outlook, as last updated on July
23, 2009, and expects to achieve annual revenues of $9.80 to $10.10 billion and
adjusted earnings per share (EPS) of $2.85 to $3.10 for the year.

Adjusted EPS is a non-GAAP measure that excludes certain items detailed later in
this press release under the heading "Use of Non-GAAP Financial Measures."

Biography

Casper has served as executive vice president and chief operating officer of
Thermo Fisher since May 2008. Prior to being named COO, Casper served as
president of Thermo Fisher`s analytical technologies businesses following the
merger of Thermo Electron and Fisher Scientific in November 2006. Casper joined
the company in December 2001 as president of its Life and Laboratory Sciences
Sector. Previously, Casper served as president, chief executive officer and a
director of Kendro Laboratory Products. Before Kendro, he was president-Americas
for Dade Behring Inc. Casper began his career at Bain & Company as a strategy
consultant and later joined Bain Capital, where he oversaw business development,
strategy and business integration in select companies owned by Bain. Casper
earned an MBA with high distinction from Harvard Business School, and is a
graduate of Wesleyan University, where he received a bachelor`s degree in
economics.

Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally
accepted accounting principles (GAAP), we use certain non-GAAP financial
measures, including adjusted earnings per share, which excludes restructuring
and other costs/income and amortization of acquisition-related intangible
assets, certain other gains and losses, tax provisions/benefits related to the
previous items, benefits from tax credit carryforwards, the impact of
significant tax audits or events and discontinued operations. We exclude the
above items because they are outside of our normal operations and/or, in certain
cases, are difficult to forecast accurately for future periods. We believe that
the use of non-GAAP measures helps investors to gain a better understanding of
our core operating results and future prospects, consistent with how management
measures and forecasts the company`s performance, especially when comparing such
results to previous periods or forecasts.

For example:

We exclude costs and tax effects associated with restructuring activities, such
as reducing overhead and consolidating facilities. We believe that the costs
related to these restructuring activities are not indicative of our normal
operating costs.

We exclude certain acquisition-related costs, including charges for the sale of
inventories revalued at the date of acquisition and significant transaction
costs. We exclude these costs because we do not believe they are indicative of
our normal operating costs.

We exclude the expense and tax effects associated with the amortization of
acquisition-related intangible assets because a significant portion of the
purchase price for acquisitions may be allocated to intangible assets that have
lives of 5 to 20 years. Our adjusted EPS estimate for 2009 excludes
approximately $.89 of expense for the amortization of acquisition-related
intangible assets for acquisitions completed through the second quarter of 2009.
Exclusion of the amortization expense allows comparisons of operating results
that are consistent over time for both our newly acquired and long-held
businesses and with both acquisitive and non-acquisitive peer companies.

We also exclude certain gains/losses and related tax effects, benefits from tax
credit carryforwards and the impact of significant tax audits or events (such as
the one-time effect on deferred tax balances of enacted changes in tax rates),
which are either isolated or cannot be expected to occur again with any
regularity or predictability and that we believe are not indicative of our
normal operating gains and losses. For example, we exclude gains/losses from
items such as the sale of a business or real estate, gains or losses on
significant litigation-related matters, gains on curtailments of pension plans,
the early retirement of debt and debt facilities, and discontinued operations.

Thermo Fisher`s management uses these non-GAAP measures, in addition to GAAP
financial measures, as the basis for measuring the company`s core operating
performance and comparing such performance to that of prior periods and to the
performance of our competitors. Such measures are also used by management in
their financial and operating decision-making and for compensation purposes.

The non-GAAP financial measure included in this press release is not meant to be
considered superior to or a substitute for a financial measure prepared in
accordance with GAAP. Thermo Fisher`s earnings guidance, however, is only
provided on an adjusted basis. It is not feasible to provide GAAP EPS guidance
because the items excluded, other than the amortization expense, are difficult
to predict and estimate and are primarily dependent on future events, such as
acquisitions and decisions concerning the location and timing of facility
consolidations.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science, enabling our customers to make the world healthier, cleaner and safer.
With 2008 revenues of $10.5 billion, we have approximately 34,000 employees and
serve over 350,000 customers within pharmaceutical and biotech companies,
hospitals and clinical diagnostic labs, universities, research institutions and
government agencies, as well as environmental and industrial process control
settings. Serving customers through two premier brands, Thermo Scientific and
Fisher Scientific, we help solve analytical challenges from routine testing to
complex research and discovery. The Thermo Scientific brand represents a
complete range of high-end analytical instruments as well as laboratory
equipment, software, services, consumables and reagents to enable integrated
laboratory workflow solutions. Fisher Scientific provides a complete portfolio
of laboratory equipment, chemicals, supplies and services used in healthcare,
scientific research, safety and education. Together, we offer the most
convenient purchasing options to customers and continuously advance our
technologies to accelerate the pace of scientific discovery, enhance value for
customers and fuel growth for shareholders and employees alike. Visit
www.thermofisher.com.

The following constitutes a "Safe Harbor" statement under the Private Securities
Litigation Reform Act of 1995: This press release contains forward-looking
statements that involve a number of risks and uncertainties. Important factors
that could cause actual results to differ materially from those indicated by
such forward-looking statements are set forth in the Company`s Quarterly Report
on Form 10-Q for the period ended June 27, 2009, under the caption "Risk
Factors," which is on file with the Securities and Exchange Commission and
available in the "Investors" section of our Website under the heading "SEC
Filings." Important factors that could cause actual results to differ materially
from those indicated by forward-looking statements include risks and
uncertainties relating to: competition and its effect on pricing, spending,
third-party relationships and revenues;the need to develop new products and
adapt to significant technological change; implementation of strategies for
improving internal growth;general worldwide economic conditions and related
uncertainties;dependence on customers` capital spending policies and government
funding policies; the effect of exchange rate fluctuations on international
operations; use and protection of intellectual property;the effect of changes in
governmental regulations;the effect of laws and regulations governing government
contracts; the effect of competing with certain of our customers and suppliers;
and the effect of rapid changes in the healthcare industry. While we may elect
to update forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so, even if our estimates change and,
therefore, you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.

Thermo Fisher Scientific Inc.
Media:
Karen Kirkwood, 781-622-1306
karen.kirkwood@thermofisher.com
Website: www.thermofisher.com
or
Investors
Ken Apicerno, 781-622-1111
ken.apicerno@thermofisher.com

Copyright Business Wire 2009